PARP1 and ovarian carcinoma: Core HR pathway genes were sequenced in 12 pairs of pre‐treatment and post‐progression tumour biopsy samples from patients in ARIEL2 Part 1, a phase II study of the PARP inhibitor rucaparib as treatment for platinum‐sensitive, relapsed ovarian cancers.